Bio/Pharma Business

Novartis Acquires Calypso Biotech for up to $425 Million

January 18, 2024

The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.

Bora Pharmaceuticals Fuels Global Expansion with Acquisition in US

January 17, 2024

The acquisition marks a pivotal expansion for the company into the US market.

Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million

January 16, 2024

Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

January 16, 2024

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

Boehringer Ingelheim Expands Facility in Greece for Production of New Therapeutics

January 15, 2024

Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.

Pluri Launches New Cell Therapy CDMO Division

January 11, 2024

Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.

Clarivate Highlights 13 Potential Drugs to Watch in Latest Report

January 10, 2024

Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

January 09, 2024

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns

January 05, 2024

MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.

Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics

January 05, 2024

Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.